SuanFarma-Header SuanFarma-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Vidofludimus calcium anhydrous

            Therapeutic Area: Immunology Product Name: IMU-838

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Immunic Therapeutics

            Deal Size: $17.2 million Upfront Cash: Undisclosed

            Deal Type: Agreement March 31, 2021

            Details:

            The acquisition of the royalties will enable Immunic to realize the full market potential of IMU-838, not only as a treatment for RRMS but also as a potential new therapeutic option for ulcerative colitis, Crohn’s disease, COVID-19, and primary sclerosing cholangitis.